[Form 4] Anavex Life Sciences Insider Trading Activity

Rhea-AI Filing Summary

Sandra Boenisch, Chief Financial Officer and Treasurer of Anavex Life Sciences Corp. (AVXL), reported the vesting and exercise of a portion of a previously granted option. A stock option granted on March 31, 2025 for 50,000 shares included four performance-based vesting tranches. One milestone was achieved, vesting 12,500 shares effective 08/20/2025. The reporting entry shows an option exercise right with an $8.58 conversion price and 12,500 underlying common shares designated as direct ownership following the transaction. The Form 4 was signed 08/22/2025 by Ms. Boenisch and discloses the triggering performance milestone as publication of specified preclinical data.

Insights

Securities Analyst

TL;DR: Insider vested and holds 12,500 shares via option exercise right after meeting a performance milestone.

The filing documents a routine, performance-driven vesting of 12,500 option shares from a 50,000-share grant made on March 31, 2025. The exercise/conversion price is $8.58 and the underlying shares are held directly after the reported transaction. For investors, this is a governance and compensation disclosure that confirms milestone achievement tied to preclinical data publication rather than an open-market purchase or sale.

Corporate Governance Expert

TL;DR: Compensation plan functioning as intended; milestone-based vesting triggered.

The disclosure indicates the company’s performance-linked equity incentives are operating per plan, with one tranche vesting after a specific scientific milestone. This is a standard governance outcome that signals alignment of executive incentives with R&D progress, without indicating material change to capital structure given the modest share count relative to public float (not disclosed here).

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boenisch Sandra

(Last) (First) (Middle)

630 5TH AVENUE

20TH FLOOR

(Street)

NEW YORK NY 10111

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAVEX LIFE SCIENCES CORP. [ AVXL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PFO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.58	08/20/2025		A		12,500(1)		08/20/2025	03/31/2035	Common Stock	12,500	$0	12,500	D

Explanation of Responses:

1. On March 31, 2025, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of preclinical blarcamesine prevention AD data. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares.

	/s/ Sandra Boenisch	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Sandra Boenisch report on Form 4 for AVXL?

She reported vesting of 12,500 option shares from a March 31, 2025 grant after a performance milestone was met, with a $8.58 conversion price.

When did the vesting event occur for the AVXL option?

The transaction date is 08/20/2025 and the Form 4 was signed on 08/22/2025.

How many shares were originally granted and how many vested?

50,000 shares were granted on 03/31/2025 and one performance tranche vested for 12,500 shares.

What performance milestone triggered the vesting?

Publication of preclinical blarcamesine prevention AD data was the milestone that resulted in vesting of the tranche.

What is the conversion or exercise price reported?

The option conversion/exercise price is $8.58 per share.